Neptune and Ingenutra sign an exclusive worldwide agreement for MaxSimil

A unique ingredient for enhanced bioavailability

Neptune Technologies & Bioressources, through its wholly owned subsidiary, Biodroga Nutraceutical, has signed an exclusive, worldwide and royalty bearing commercial agreement with Ingenutra for its patented and clinically studied MaxSimil specialty ingredient.

Designed as a unique delivery system, MaxSimil allows for enhanced bioavailability and absorption of lipid based and lipid soluble nutraceutical ingredients such as omega-3 fish oils, vitamin A, D, K and E, CoQ10 and others.

The agreement allows Neptune to manufacture, distribute and sell MaxSimil in the nutraceutical field worldwide. The terms also cover potential collaboration between both companies on clinical trials.

The agreement is valid until 2028 and supersedes a previous arrangement between Biodroga and Ingenutra that was limited to North America. All other terms of the agreement remain confidential.

Francois-Karl Brouillette, Vice-President Scientific Affairs of Neptune, stated: 'Increasing the bioavailability and absorption of EPA and DHA in a natural way is truly amazing. MaxSimil now makes it possible for everyone, including people suffering from compromised digestive health, to properly assimilate their healthy fats. We are very proud to make this ingredient accessible worldwide. This is what Neptune and our industry are all about: improving the quality of life of consumers through healthy nutrition solutions.'

Serge Brunet, President of Ingenutra, added: 'I am proud of this new partnership with Neptune. I am confident that they will provide the steppingstone that will allow the benefits of MaxSimil to be recognised worldwide through Neptune's well established and growing network.'

Recently, one of Neptune's clients, XYMOGEN, launched the MonoPure line of omega-3 EPA+DHA products based on Maxsimil. It is aimed at the practitioner market in the United States.

Companies